

# Antimicrobial peptide-peptoid hybrids to control multidrug resistant Gram-negative bacteria

E. Bonvin[1], J. L. Reymond[1]*

[1]University of Bern, Department of Chemistry, Biochemistry and Pharmaceutical Sciences

Membrane disruptive antimicrobial peptides (AMPs) such as polymyxin B offer an opportunity to control multidrug resistant (MDR) Gram-negative bacteria,[1] which are a leading cause of death in hospitals.[2] Recently we discovered that inverting the chirality of lysine amino acids in an 11-residues α-helical AMP with strong activity against these bacteria preserved its α-helical folding and activity while abolishing its hemolytic properties and serum instability.[3] Inspired by several reports of using peptoid building blocks to tune AMP activity,[4] we investigated if our AMP activity might also be tolerant to peptoid substitutions. Our investigations revealed several peptide-peptoid hybrids with preserved α-helical folding and antibacterial activity, but increased serum stability and reduced hemolysis compared to the parent all-L AMP sequence (Figure). Additionally, even if helicity was lacking, several hybrids including the full peptoid displayed strong antibacterial effect under dilute medium conditions, typically used for proline-rich antimicrobial peptides,[5] suggesting a transition from membrane disruption to intracellular targets.




[1] N. Mookherjee, M. A. Anderson, H. P. Haagsman and D. J. Davidson, *Nat Rev Drug Discov*, **2020**, 19, 311–332.
[2] C. J. Murray *et al.*, *The Lancet*, **2022**, 399, 629–655.
[3] S. Baeriswyl, H. Personne, I. D. Bonaventura, T. Köhler, C. van Delden, A. Stocker, S. Javor and J.-L. Reymond, *RSC Chemical Biology*, **2021**, 2, 1608–1617.
[4] T. Godballe, L. L. Nilsson, P. D. Petersen and H. Jenssen, *Chemical Biology & Drug Design*, **2011**, 77, 107–116.
[5] D. Knappe, S. Piantavigna, A. Hansen, A. Mechler, A. Binas, O. Nolte, L. L. Martin and R. Hoffmann, *J. Med. Chem.*, **2010**, 53, 5240–5247.